Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)

Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)

PI Institution(s)

Principal Investigator (PI)



This is an initial efficacy study of a candidate antimalarial in human subjects with uncomplicated malaria caused by the most common and most important parasite in Africa (Plasmodium falciparum). This study will enroll 66 adult Malian males with uncomplicated P. falciparum malaria and randomize them to treatment with 1750 mg of the investigational drug (AQ-13) by mouth over 3 days or the current standard treatment, which is 4 tablets of Coartem twice daily for 3 days. The hypothesis underlying this study is that AQ-13 will be similarly effective to Coartem for the treatment of uncomplicated P. falciparum malaria due to both chloroquine-susceptible and chloroquine-resistant parasites

Key facts

  • Dates
    Aug 2013 to Jun 2016
    • Mali

MESA tags

  • Methodology
    Product development & clinical research